COGT241220C5000
- 5.60
- 0.000.00%
Cogent Biosciences Newsroom
Needham Downgrades Cogent Biosciences to Hold, Maintains Price Target to $15
Express News | Cogent Biosciences Inc : Needham Cuts to Hold From Buy
Needham Downgrades Cogent Biosciences(COGT.US) to Hold Rating, Maintains Target Price $15
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $17
Cogent Biosciences Price Target Maintained With a $15.00/Share by Needham
Cogent Biosciences Analyst Ratings
Leerink Partners Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $16
Promising Market Potential for Cogent Biosciences: A Buy Rating Backed by Efficacy and Safety of Bezuclasinib
Why Is Cogent Biosciences Stock Trading Higher On Monday?
Express News | Cogent Biosciences Inc : Leerink Partners Raises Target Price to $16 From $15
Express News | Cogent Biosciences Shares Are Trading Lower. The Company Presented Data on Bezuclastinib for Mastocytosis at ASH 2024
Cogent Biosciences Reports Updated Results From Trial of Bezuclastinib
Express News | Cogent Biosciences Inc: Top-Line Results Now Expected in July 2025
Express News | Cogent Biosciences: 56% Mean Improvement in Total Symptom Score at 24 Weeks With 76% of Patients Achieving at Least a 50% Reduction in Tss
Express News | Cogent Biosciences: Updated Clinical Results From Open Label Extension Portion of Summit Trial
Needham Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $15
Strong Efficacy and Safety Profile of Cogent Biosciences' Bezu in Adv SM Outshines Competitors
Cogent Biosciences Announces Positive Updated Data From Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients With Advanced Systemic Mastocytosis (AdvSM)
Piper Sandler Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $23
Express News | Cogent Biosciences Inc : Guggenheim Cuts Target Price to $17 From $20